Compare Amcor PLC (AMCR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amcor PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Amcor PLC trades at $43 (market cap $19.96B), while State Street SPDR S&P Biotech ETF trades at $158.7. The key difference: Amcor PLC pays a 6.02% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Amcor PLC nearer its low. Which is the better fit depends on your goals.
| AMCR | XBI | |
|---|---|---|
Market Cap | $19.96B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $50.58 | $164.28 |
52-Week Low | $36.69 | $85.16 |
Enterprise Value | $35.08B | — |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
XBI, the SPDR S&P Biotech ETF, trades at $159.03, down 3.2% over the past day amid a broader market pullback, though it remains in a strong uptrend with a 17% gain over the past month. Technical indicators are bullish overall, but RSI levels suggest overbought conditions. The ETF's equal-weight exposure to biotech stocks drives high volatility and significant upside during sector rallies, with recent news highlighting booming biotech M&A and AI-driven drug discovery as key catalysts.
The outlook for XBI is positive given sector momentum and favorable deal activity, though its high beta and reliance on small- to mid-cap biotech stocks pose risks during market downturns. Analyst sentiment is neutral with a single hold rating, reflecting caution amid elevated valuations. Investors should weigh the sector's growth potential against inherent volatility and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
